126
Participants
Start Date
July 19, 2017
Primary Completion Date
September 1, 2025
Study Completion Date
September 1, 2028
Pembrolizumab
Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
Chris O'Brien Hospital, Camperdown
Peter MacCallum Cancer Centre, Melbourne
Princess Alexandra Hospital, Brisbane
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh (UPMC Hillman Cancer Center), Pittsburgh
University of Pennsylvania- Abramson Cancer Center, Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Johns Hopkins University, Baltimore
Duke University, Durham
Mayo Clinic- Florida, Jacksonville
The Ohio State University, Columbus
University of Michigan, Ann Arbor
University of Iowa Hospitals & Clinics, Iowa City
Washington University, St Louis
University of Kansas Medical Center, Kansas City
University of California Los Angeles, Los Angeles
Oregon Health & Science University, Portland
Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Cancer Institute, Boston
McGill University Health Centre, Montreal
Stand Up To Cancer
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Sarcoma Alliance for Research through Collaboration
OTHER